poisar

Stocks · News reference

Merck And Moderna Announce Topline Results From The Phase 3 Interpath-001 Trial Evaluating Adjuvant Treatment With Intismeran Autogene In Combination With KEYTRUDA In Patients With Completely Resected Stage IIB-IV Melanoma; At A Pre-specified Interim Analysis, Intismeran In Combination With KEYTRUDA As Adjuvant Therapy Demonstrated Statistically Significant And Clinically Meaningful Improvements In RFS And DMFS Compared To KEYTRUDA Alone

Aug 19, 2026, 10:47 AMBenzinga News-desk

Merck (NYSE:MRK), known as MSD outside of the United States and Canada, and Moderna, Inc. (NASDAQ:MRNA) today announced positive topline results from the Phase 3 INTerpath-001 trial evaluating adjuvant treatment with

Read original sourceMore stocks news

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

MRKMRNA
Source
benzinga
Observed
Aug 19, 2026, 10:47 AM
Checked
Aug 19, 2026, 10:47 AM
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Aug 27, 2026, 4:11 PMNa

    SMMT Rises on Akeso's Win in Phase III Biliary Tract Cancer Study

    Summit Therapeutics' partner Akeso announced positive phase III HARMONi-GI1 study results showing ivonescimab plus chemotherapy achieved superior overall survival compared to AstraZeneca's Imfinzi plus chemotherapy in advanced biliary tract cancer patients. The drug also met key secondary endpoints for progression-free survival and objective response rate. These results strengthen ivonescimab's development case beyond its initial NSCLC focus into colorectal and genitourinary cancers.

    Read original at zacks-investment-research
    SMMTAZNMRK